id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-P-1820-0003,FDA,FDA-2026-P-1820,Attachment 1 - Tolmetin Capsules - OB Page,Supporting & Related Material,Background Material,2026-02-19T05:00:00Z,2026,2,,,2026-02-19T22:23:47Z,,0,0,09000064b91c1073
FDA-2026-P-1820-0005,FDA,FDA-2026-P-1820,Attachment 3 - RS Approved Labeling,Supporting & Related Material,Background Material,2026-02-19T05:00:00Z,2026,2,,,2026-02-19T22:23:52Z,,0,0,09000064b91c107e
FDA-2026-P-1820-0001,FDA,FDA-2026-P-1820,"Suitability Petition from Senores Pharmaceuticals, Inc.",Other,Petition(s),2026-02-19T05:00:00Z,2026,2,2026-02-19T05:00:00Z,,2026-02-19T22:18:35Z,,1,0,09000064b91bf15b
FDA-2026-P-1820-0002,FDA,FDA-2026-P-1820,"Acknowledgement Letter from FDA DMB to Senores Pharmaceuticals, Inc.",Other,Acknowledgement Letter/Receipt,2026-02-19T05:00:00Z,2026,2,2026-02-19T05:00:00Z,,2026-02-19T22:23:17Z,,0,0,09000064b91bf15c
FDA-2026-P-1820-0004,FDA,FDA-2026-P-1820,Attachment 2 - Tolmetin Tablets 200 mg - OB Page,Supporting & Related Material,Background Material,2026-02-19T05:00:00Z,2026,2,,,2026-02-19T22:23:50Z,,0,0,09000064b91c1076
FDA-2026-P-1820-0006,FDA,FDA-2026-P-1820,Attachment 4 - Proposed Labeling for Tolmetin Capsules 200 mg,Supporting & Related Material,Background Material,2026-02-19T05:00:00Z,2026,2,,,2026-02-19T22:23:54Z,,0,0,09000064b91c1080